Home › Trials › NCT07155174

ABBV-706 plus atezolizumab versus standard first-line therapy for extensive-stage small cell lung cancer

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 2 Interventional AbbVie · NCT07155174

This trial will test whether giving ABBV-706 with atezolizumab is safer or more effective than standard first-line chemo plus atezolizumab in adults with previously untreated extensive-stage small cell lung cancer.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment180 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsatezolizumab
Locations34 sites (New Haven, Connecticut and 33 other locations)
Trial IDNCT07155174 on ClinicalTrials.gov

What this trial studies

Adults with previously untreated extensive-stage SCLC and ECOG 0–1 will be enrolled at multiple sites and receive either one of two IV doses of ABBV-706 with IV atezolizumab or the standard regimen of etoposide, carboplatin and atezolizumab (with optional lurbinectedin). The study includes a safety lead-in to define tolerable ABBV-706 dosing followed by an expansion phase to compare adverse events and change in disease activity across arms, targeting about 180 participants worldwide. Key eligibility requires measurable disease and brain imaging to rule out active symptomatic CNS metastases, while major exclusions include prior limited-stage therapy and active interstitial lung disease. Primary outcomes focus on safety, optimal dose selection, and change in disease activity measured by RECIST v1.1.

Who should consider this trial

Good fit: Adults with newly diagnosed extensive-stage small cell lung cancer who have not received prior systemic therapy, have measurable disease, and have ECOG performance status 0–1 are ideal candidates.

Not a fit: Patients with active symptomatic brain metastases, prior treatment for limited-stage SCLC, active interstitial lung disease or pneumonitis requiring steroids, or ECOG >1 are unlikely to be eligible or to benefit from this trial.

Why it matters

Potential benefit: If successful, the combination could produce higher tumor response rates or longer time to progression than current first-line treatment, offering a new option for patients.

How similar studies have performed: Adding atezolizumab to chemotherapy has previously improved survival in first-line ES-SCLC, but ABBV-706 is investigational and combining this type of agent with immunotherapy is a novel approach with mixed results in earlier efforts.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
* Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
* Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.

Exclusion Criteria:

* Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
* Known active/symptomatic central nervous system (CNS) metastases should be excluded.
* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded.
* Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.

Where this trial is running

New Haven, Connecticut and 33 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Small Cell Lung CancerSCLCABBV-706EtoposideCarboplatinAtezolizumabLurbinectedin
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.